Galectin Therapeutics (GALT) Reports Q2 Loss of $0.14/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mail
Get Alerts GALT Hot Sheet
Join SI Premium – FREE
Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.14), versus ($0.20) reported last year.
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Why Beijing could block the SpaceX-Tesla merger
- Arbor Realty Trust (ABR) Misses Q3 EPS by 8c
- Top AdTech stocks to watch as third quarter earnings approach - B Riley
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
